External evaluation of population pharmacokinetic models of imatinib in adults diagnosed with chronic myeloid leukaemia.
Álvaro Corral AlaejosAranzazu Zarzuelo CastañedaSilvia Jiménez CabreraFermin M Sanchez-GuijoMarà A Josà OteroJonás Samuel Pérez-BlancoPublished in: British journal of clinical pharmacology (2021)
Imatinib popPK studies developed in Caucasian subjects including α1-acid glycoprotein showed the best model performance in terms of overall bias and precision. Moreover, two imatinib samples from different visits appear sufficient to reach an adequate model-based individual prediction performance trough Bayesian forecasting.